Compounded Semaglutide, Explained

A compounded drug is made by combining, mixing or altering ingredients rather than manufactured under an approved application. Federal law leaves room for that because some medical needs genuinely cannot be met off the shelf. What it does not do is put the result on the same regulatory footing as an approved drug. Compounded drugs are not FDA approved, which means FDA does not verify the safety, effectiveness or quality of a compounded drug before it is marketed. That single sentence is the whole difference, and it applies to every compounded semaglutide product sold in the United States today.

Two sections of the Food, Drug, and Cosmetic Act define who may compound. Under section 503A a licensed pharmacist in a state-licensed pharmacy, or a physician, compounds for one prescription at a time, and state boards of pharmacy hold primary day-to-day oversight. Under section 503B an outsourcing facility registers with FDA, is inspected on a risk-based schedule, and must follow current good manufacturing practice. Drugs compounded under 503A are not subject to those manufacturing requirements at all.

The practical consequence is that two vials labeled compounded semaglutide can come from very different operations. One may have been made in a facility FDA has walked through and tested. The other may have been made in a pharmacy FDA has never inspected, under rules set by a state board rather than a federal manufacturing standard. Nothing on the label reliably tells you which. Asking which section the compounder operates under is a fair question, and the answer is verifiable.

The shortage-based route is closed. Semaglutide injection went on FDA's shortage list in March 2022 for one product and August 2022 for the other, and FDA issued a declaratory order on February 21, 2025 determining that the shortage was resolved. Because shortage status is what suspends the restriction on compounding essentially a copy of an approved drug, removing semaglutide from that list removed the permission most compounders had been relying on. Then came the deadlines and the litigation, and both are now settled. FDA's own timeline records that the district court denied the compounders' preliminary injunction on April 24, 2025, ending the 503A enforcement discretion period, and that the 503B period ran only until May 22, 2025. The trade association appealed. On August 27, 2026 the Fifth Circuit affirmed the judgment against them, holding that any procedural error by FDA was harmless and the delisting was not arbitrary or capricious.

One piece is genuinely unresolved, so treat anyone who tells you the question is closed with caution. On May 1, 2026 FDA proposed not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list, finding no clinical need, and extended the comment period to July 30, 2026 under docket FDA-2018-N-3240. No final determination has been published. Meanwhile 503A compounding continues where a prescriber documents a significant difference for one named prescription, which is why the products are still being sold.

Here is the honest picture, and it is smaller than the marketing suggests. The efficacy figures circulating online come from the trial programs behind the approved products. A compounded vial is a different formulation, from a different maker, at a strength nobody outside that pharmacy has measured, so those figures do not transfer to it. A 2026 review in Annals of Pharmacotherapy put it plainly after cataloguing what was on sale: the popularity of these products as an alternative to FDA-approved medications is concerning, given the lack of evidence for safety and efficacy.

There is one real outcome study, and its limits matter more than its result. A retrospective review of a commercial wellness program followed 94 adults on weekly compounded semaglutide with cyanocobalamin and recorded mean weight loss of 4.11 kg, or 4.57 percent, at three months. There was no control group, no randomization, no blinding, and the program that sold the injections ran the analysis. Treat it as a signal. It is not a measurement, and it sits well below what the approved products report in their own trials.

This is the detail most buyers never look for, and it is the one most worth checking. FDA has stated that some compounders sell salt forms and that semaglutide sodium and semaglutide acetate are different active ingredients than are used in the approved drugs. The agency adds that it does not have information on whether those salts share the chemical and pharmacologic properties of the base form, and that it is not aware of any lawful basis for their use in compounding.

That is a stronger statement than it looks. It is not a warning that the salts are weaker or stronger. It is a statement that nobody has established what they do, and that the legal footing for using them is absent. If a compounder or a telehealth service will not tell you which form is in the vial, or the paperwork names a salt, you are outside even the contested part of the law. Ask for the certificate of analysis and read the ingredient line rather than the marketing page.

The mechanism of harm here is arithmetic. Pharmacology has nothing to do with it.

Approved injectable semaglutide is supplied in pens that deliver a set dose. Compounded semaglutide frequently arrives as a vial and a syringe, with instructions written in units rather than milligrams, at a concentration that varies between compounders. FDA has received reports of adverse events, some requiring hospitalization, from dosing errors with compounded injectable semaglutide, with reported overdoses of five to twenty times the intended dose.

The clearest documented case is a unit-scale misread. FDA describes prescriptions written for 5 units, or 0.05 mL, drawn from a vial with a U-100 insulin syringe, where 50 units were administered instead of 5. Prescribers make the same class of error: one intended 0.25 mg and wrote 25 units instead of 5, and another wrote 20 units instead of 2, affecting three separate prescriptions. A regional poison center published three cases of compounded semaglutide administration errors, two of them ten-fold overdoses as early as 2023.

Semaglutide has a half-life of about a week, so an overdose is not an evening of feeling unwell. FDA notes that a prolonged period of observation and treatment may be necessary. Reported effects include severe nausea and vomiting, abdominal pain, fainting, dehydration, acute pancreatitis and gallstones. If you are handed a vial and a syringe, ask your prescriber to show you the exact volume for your dose, in milliliters, and to confirm the syringe size matches it before you inject anything.

The reported numbers are real, and every one of them is a floor. As of May 31, 2026 FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The agency notes in the same place that federal law does not require state-licensed pharmacies outside the outsourcing-facility system to report adverse events at all, so underreporting is likely. Many reported effects match those seen with the approved products, and some do not.

Storage is where a compounded vial is most exposed. FDA recommends discarding a multi-dose sterile vial within 28 days after first use, even if medication remains, and even if the compounder's instructions say otherwise, and using a new sterile needle and syringe every time. The agency has also received complaints of compounded GLP-1 shipments arriving warm or with inadequate ice, and advises against using them. If a package arrives at room temperature, photograph it and contact the pharmacy rather than injecting it.

Content and purity are a separate question from dose. A 2026 analysis found that compounded and follow-on semaglutide samples carried distinct impurity profiles and potentially immunogenic peptides compared with the originator product, with significant disparity in strength and high-molecular-weight protein after light exposure. Read that with its conflict of interest in view: every author was employed by or held shares in the company that makes the approved product. It is a reason to ask for testing data. It is not a settled finding.

Additives are not a bonus, they are usually the legal mechanism. A survey of compounding websites between February and March 2025 identified 33 distinct compounded semaglutide and tirzepatide products, of which 48 percent combined the drug with some mix of cyanocobalamin, glycine, niacinamide, docusate or ondansetron. Since the shortage ended, a compounded product generally has to differ from the approved one, and a second ingredient is the cheapest way to make it differ on paper.

FDA has anticipated that move directly. Its guidance uses semaglutide combined with vitamin B12 as its worked example of a product that may still count as essentially a copy when the strengths land within ten percent of the commercially available products and the route of administration is the same. The same document notes FDA does not intend to act against a compounder filling four or fewer such prescriptions in a calendar month, which is a narrow allowance rather than a general one.

Clinically, the additives are thin. The authors of that 33-product survey found little justification for adding nutrients or docusate sodium to injectable semaglutide, saw a rationale for ondansetron but no evidence supporting it by injection, and reported that only 18 percent of the products listed both a beyond-use date and storage conditions. If your vial contains something besides semaglutide, ask your prescriber what that ingredient is doing and what evidence supports it at that dose.

The rule is narrower than the market. FDA's stated position is that compounded drugs should only be used where medical needs cannot be met by an FDA-approved drug, and under 503A a compounded version of a commercially available drug generally needs a prescriber to determine and document that it contains a change producing a significant difference for one named prescription. A documented allergy to an excipient, or a strength no approved presentation delivers, is the shape of a reason that qualifies.

Cost is not. Price is a real constraint and it drives most of this market, but it is not a clinical difference and it does not appear anywhere in the compounding conditions. Nothing on this page is medical advice, and only the clinician writing your prescription can judge whether compounding fits your situation. If your intake form never asked why an approved product would not work for you, and no clinician discussed that with you, the documentation that makes your prescription lawful may not exist. That is worth knowing before you build a year of treatment on it.

Across the 12 active weight-loss platforms in our own price index, advertised starting prices ran from $59 to $199 a month when we last verified them on August 21, 2026. The $59 figure is a membership that excludes medication; the cheapest programs that include it start around $99. Those are entry prices at the lowest dose, and most of them rise as a dose is titrated up, so compare the price at the dose you expect to reach rather than the one on the landing page.

The gap against approved products is genuine, and so is what it reflects. An approved drug carries the cost of a trial program, a premarket review and inspected manufacturing. A compounded vial does not, which is most of why it costs less. It is a legitimate trade to consider with a clinician who knows your history, and it is a different question from whether the product works. Also ask a commercial question: what your monthly cost becomes, and whether your supply continues, if the pending 503B decision or a state action removes the compounded route.

Start with the label, because this check takes two minutes. The only semaglutide products holding an FDA approval are Ozempic, Wegovy and Rybelsus, all from a single manufacturer, which you can confirm yourself in Drugs@FDA or by reading the approved labeling in DailyMed. If the carton says compounded, names a pharmacy as the maker, or carries a strength or a combination you cannot find in either database, it came through a compounding route and no approved label applies to it.

Then check the maker rather than the website that sold it. FDA publishes the list of registered outsourcing facilities, so a 503B facility is verifiable by name in a minute; a 503A pharmacy should be verifiable through its state board, and FDA's BeSafeRx tool will locate a state-licensed online pharmacy. FDA's own red flags for telehealth services include deep discounts, medication that arrives looking different from what was pictured, no licensed clinician available after delivery, and a claim that the compounded drug is the same as an FDA-approved drug.

Four questions get you the rest. Which section does the compounder operate under, 503A or 503B, and what is its name. Which form of semaglutide is in the vial, base or a salt, and can you see the certificate of analysis. What is the concentration in milligrams per milliliter, and what exact volume equals my dose. What else is in the vial and why.

A service that answers all four in writing is behaving well; one that treats those questions as unreasonable has told you something.